Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Open-label Phase II Study of Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

NCT03757221 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.

NCT NCT03757221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03757221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Open-label Phase II Study of Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
Lead sponsor
University Hospital, Caen
Phase
Phase 2
Overall status
Terminated
Start date
February 7, 2019
Completion date
April 28, 2024
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma